Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
PR Newswire
Report Store
UsernamePublicRestriction
Tags:
Medical Device

Medtronic Revo MRI Pacer Approved, But Still Faces Reimbursement Hurdle

This article was originally published in The Gray Sheet

  • News

Executive Summary

Medtronic is hoping that the immediate U.S. launch of its newly approved Revo MRI SureScan MRI-compatible pacemaker will help boost market share in the device category, but magnetic resonance imaging scans of implant recipients still face a key reimbursement hurdle.

You may also be interested in...



New Products In Brief

Bionic eye, MRI-safe pacemaker are among recent new product approvals.

New Products In Brief

Mela Sciences launches MelaFind melanoma detection device in the U.S. Medtronic launches CapSure Sense MRI SureScan pacing leads overseas. More product news.

St. Jude Announces Key Approvals On Top Of Q1 Results

St. Jude Medical last week announced two important regulatory approvals: a CE mark in Europe for its MRI-friendly pacemaker and an FDA PMA approval for its anticipated stented pericardial tissue heart valve device.

Table

View full table

Related Content

Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight
Medtech Insight

Topics

Tags:
Medical Device
UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By